Trials / Unknown
UnknownNCT06201715
Efficacy and Safety of Tofacitinib in Patients With Prurigo Nodularis
Efficacy and Safety of Tofacitinib in Patients With Prurigo Nodularis: a Prospective, Observational Pilot Study
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal is to evaluate the efficacy and safety of tofacitinib in treating refractory prurigo nodularis.The main questions it aims to answer are 1. whether tofacitinib is effective in treating prurigo nodularis in the longpterm. 2. whether tofacitinib is safe in prurigo nodularis patients in the longpterm.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tofacitinib 5 MG | 5mg tofacitinib tablet twice daily |
Timeline
- Start date
- 2024-05-01
- Primary completion
- 2025-06-30
- Completion
- 2025-12-30
- First posted
- 2024-01-11
- Last updated
- 2024-04-01
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06201715. Inclusion in this directory is not an endorsement.